Literature DB >> 11325084

Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis.

H B Joshi1, A Stainthorpe, F X Keeley, R MacDonagh, A G Timoney.   

Abstract

BACKGROUND: Ureteral stents cause various side effects. We have evaluated health-related quality of life (HRQoL) in patients with stents using validated questionnaires and developed a new stent symptom (intervention)-specific questionnaire (SSQ). PATIENTS AND METHODS: Along with structured literature review and in-depth interviews, prospective sub-studies were carried out using generic (SF-36 [N = 30], EuroQol [N = 40], and Functional Status Questionnaire FSQ [N = 20]) and symptom-specific (IPSS [N = 30] and International Continence Society ICS [N = 30]) questionnaires both with a stent in situ and after removal. The results of these studies formed the foundation for a new SSQ that was pilot tested (N = 10) and field tested (N = 20) in order to develop a final draft of the questionnaire that is formally validated.
RESULTS: The qualitative research identified a range of problems. Urinary symptoms, pain, work performance, and general health were the most important. Most patients (80%) experienced bothersome urinary symptoms and stent-related pain. Storage symptoms and incontinence were significant urinary symptoms affecting quality of life. As many as 40% of patients experienced sexual dysfunction. The stent had a significant impact on patients' general health. None of the existing measures evaluated the complete impact. The SSQ includes five sections covering urinary symptoms, pain, sexual matters, general health, and work performance. The preliminary results showed it to be valid, reliable (alpha > 0.7) and responsive to the change in scores (p < 0.05) after stent removal.
CONCLUSIONS: Indwelling ureteral stents are associated with significant morbidity, resulting in a reduced HRQoL in 80% of patients. The SSQ is a reliable intervention-specific instrument that would be useful as an outcome measure to evaluate the impact of stents.

Entities:  

Mesh:

Year:  2001        PMID: 11325084     DOI: 10.1089/089277901750134421

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  30 in total

Review 1.  Current status of ureteral stent technologies: comfort and antimicrobial resistance.

Authors:  Carlos E Mendez-Probst; Alfonso Fernandez; John D Denstedt
Journal:  Curr Urol Rep       Date:  2010-03       Impact factor: 3.092

2.  Freeze-casting porous chitosan ureteral stents for improved drainage.

Authors:  Kaiyang Yin; Prajan Divakar; Ulrike G K Wegst
Journal:  Acta Biomater       Date:  2018-11-07       Impact factor: 8.947

3.  Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts.

Authors:  Kyoung Taek Lim; Yong Tae Kim; Tchun Yong Lee; Sung Yul Park
Journal:  Korean J Urol       Date:  2011-07-24

4.  Outcomes of Ureteral Stent Placement for Hydronephrosis in Patients with Gynecological Malignancies.

Authors:  Saya Kurata; Shohei Tobu; Kazuma Udo; Mitsuru Noguchi
Journal:  Curr Urol       Date:  2017-07-30

5.  Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis.

Authors:  Zhongyu Jian; Yuntian Chen; Qinyu Liu; Banghua Liao; Tongxin Yang; Hong Li; Kunjie Wang
Journal:  World J Urol       Date:  2018-07-20       Impact factor: 4.226

6.  Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study.

Authors:  Chung-Jing Wang; Shi-Wei Huang; Chien-Hsing Chang
Journal:  Urol Res       Date:  2009-03-10

7.  Assessing the impact of ureteral stent design on patient comfort.

Authors:  James E Lingeman; Glenn M Preminger; Evan R Goldfischer; Amy E Krambeck
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

8.  The German linguistic validation of the Ureteral Stent Symptoms Questionnaire (USSQ).

Authors:  Dominik Abt; Kristina Dötzer; Patrick Honek; Karolina Müller; Daniel Stephan Engeler; Maximilian Burger; Hans-Peter Schmid; Thomas Knoll; Francesco Sanguedolce; Hrishi B Joshi; Hans-Martin Fritsche
Journal:  World J Urol       Date:  2016-06-23       Impact factor: 4.226

9.  Intraureteral lidocaine for ureteral stent symptoms post-ureteroscopy: A randomized, phase 2, placebo-controlled trial.

Authors:  Gregory Roberts; Robert Leslie; Sylvia Robb; D Robert Siemens; Darren Beiko
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862

10.  Ureteral stent discomfort: Etiology and management.

Authors:  Ricardo Miyaoka; Manoj Monga
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.